Delisting risk
Lakewood-Amedex Biotherapeutics
Develops topical Nu-3 gel for mildly infected diabetic foot ulcers.
$2.95
Pre-market+0.44 (+17.55%)
At close$2.51(+9.13%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | |
| Research & development | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |
| 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |
| Net income from continuing operations | −1 | −1 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |
| Net income | −1 | −1 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |
| EPS, basic | −$1.46 | −$1.53 | −$2.79 | $0.00 | −$1.50 | −$1.66 | −$1.37 | −$3.90 | −$2.00 | −$2.75 |
| EPS, diluted | −$1.46 | −$1.53 | −$2.79 | $0.00 | −$1.50 | −$1.66 | −$1.37 | −$3.90 | −$2.00 | −$2.75 |
| Weighted average shares, basic | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| Weighted average shares, diluted | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −1 | −2 | −1 | −1 | −4 |